Date: 2015-01-13
Type of information: Collaboration agreement
Compound: cell lines for GMP manufacture of two anti-CD40-HIV fusion proteins
Company: Antitope, an Abzena company (UK) ANRS (France) Inserm (France) The Baylor Institute for Immunology Research (USA - TX)
Therapeutic area: Infectious diseases
Type agreement: collaboration
Action mechanism:
Disease: HIV infection
Details: * On January 12, 2015, Abzena announced its wholly-owned subsidiary Antitope has extended its relationship with INSERM, the French National Institute of Health and Medical Research, a leading public scientific and technological institute with a key role in biomedical and translational research; ANRS, the National Health Agency for Research on AIDS and Hepatitis; and the Baylor Institute for Immunology Research (“BIIR”), one of the world’s leading centers for translational immunology research. INSERM-ANRS and the BIIR have developed innovative approaches for HIV vaccines targeting HIV antigens to dendritic cells (DC) using monoclonal antibodies fused to HIV antigens. Extensive preclinical data has demonstrated the high immunogenicity of the candidate vaccines. Antitope will produce cell lines for GMP manufacture of two anti-CD40-HIV fusion proteins that INSERM-ANRS and BIIR are developing as potential therapeutic and prophylactic vaccines to treat HIV. The cell lines will be produced using Antitope’s Composite CHO™ technology. The antibody component of the fusion proteins has previously been humanized by Antitope using its Composite Human Antibody™ technology. Phase I and Phase II clinical trials will be conducted in France to test the immunogenicity and efficacy of these DC-targeting vaccines developed by INSERM-ANRS in partnership with the BIIR.
Financial terms:
Latest news:
